Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 98Stomach Neoplasms 50Rectal Neoplasms 45Pancreatic Neoplasms 45Colonic Neoplasms 36Esophageal Neoplasms 34Neoplasms 30Neoplasm Metastasis 28Squamous Cell Carcinoma of Head and Neck 27Head and Neck Neoplasms 24Breast Neoplasms 21Adenocarcinoma Of Esophagus 20Parkinson Disease 4, Autosomal Dominant Lewy Body 12Adenocarcinoma 9Anus Neoplasms 8Esophageal Squamous Cell Carcinoma 7Carcinoma, Squamous Cell 7Carcinoma 7Cholangiocarcinoma 6Liver Neoplasms 5Gallbladder Neoplasms 5Bile Duct Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Adenocarcinoma 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Skin Neoplasms 3Sarcoma 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2 Positive Esophagogastric Cancer × Fluorouracil × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡